The FDA on May 4, 2018 approved TAFINLARĀ® (Dabrafenib) and MEKINISTĀ® (Trametinib) for Anaplastic Thyroid Cancer with BRAF V600E mutation. TAFINLARĀ® and MEKINISTĀ® are products of Novartis Pharmaceuticals Corp.
Other Pages – Bottom Ad
Advertisement
Subscribe
